For a mechanistic understanding of the neutral effect of the therapeutic dose of E4 on breast tumor growth, we defined the potency of E4 to activate ERα signaling in vitro on MCF7 and T47D cells and in vivo in human MCF7 and PDX tumors. Here, ESR1 is linked to breast neoplasm.